{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:48:42Z","timestamp":1791978522116,"version":"4.4.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T00:00:00Z","timestamp":1646438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T00:00:00Z","timestamp":1646438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00228-022-03303-4","type":"journal-article","created":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T00:02:30Z","timestamp":1646438550000},"page":"931-942","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Selective serotonin reuptake inhibitors in the treatment of depression, anxiety, and post-traumatic stress disorder in substance use disorders: a Bayesian meta-analysis"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9272-2259","authenticated-orcid":false,"given":"Dimy","family":"Fluyau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paroma","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasanth Kattalai","family":"Kailasam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,5]]},"reference":[{"issue":"2","key":"3303_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/s0740-5472(00)00094-5","volume":"19","author":"KB Carey","year":"2000","unstructured":"Carey KB, Purnine DM, Maisto SA, Carey MP, Simons JS (2000) Treating substance abuse in the context of severe and persistent mental illness: clinicians\u2019 perspectives. J Subst Abuse Treat 19(2):189\u2013198. https:\/\/doi.org\/10.1016\/s0740-5472(00)00094-5","journal-title":"J Subst Abuse Treat"},{"key":"3303_CR2","doi-asserted-by":"publisher","unstructured":"Dickey B, Azeni H (1996) Persons with dual diagnoses of substance abuse and major mental illness: their excess costs of psychiatric care. Am J Public Health 86(7):973\u2013977. https:\/\/doi.org\/10.2105\/ajph.86.7.973","DOI":"10.2105\/ajph.86.7.973"},{"key":"3303_CR3","doi-asserted-by":"publisher","unstructured":"Quello SB, Brady KT, Sonne SC (2005) Mood disorders and substance use disorder: a complex comorbidity.\u00a0Sci Pract Perspect 3(1):13\u201321. https:\/\/doi.org\/10.1151\/spp053113","DOI":"10.1151\/spp053113"},{"key":"3303_CR4","doi-asserted-by":"crossref","unstructured":"Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, Shea MT, Keller MB (2005) Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study.\u00a0Am J Psych 162(6):1179\u20131187. https:\/\/doi.org\/10.1176\/appi.ajp.162.6.1179","DOI":"10.1176\/appi.ajp.162.6.1179"},{"key":"3303_CR5","doi-asserted-by":"publisher","unstructured":"Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB (1995) Post-traumatic stress disorder in the National Comorbidity Survey.\u00a0Arch Gen Psych 52(12):1048\u20131060. https:\/\/doi.org\/10.1001\/archpsyc.1995.03950240066012.","DOI":"10.1001\/archpsyc.1995.03950240066012"},{"issue":"3","key":"3303_CR6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.neuropharm.2011.03.022","volume":"61","author":"LG Kirby","year":"2011","unstructured":"Kirby LG, Zeeb FD, Winstanley CA (2011) Contributions of serotonin in addiction vulnerability. Neuropharmacology 61(3):421\u2013432. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.03.022","journal-title":"Neuropharmacology"},{"issue":"3","key":"3303_CR7","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.neures.2011.03.004","volume":"70","author":"J Kleijn","year":"2011","unstructured":"Kleijn J, Cremers TI, Hofland CM, Westerink BH (2011) CB-1 receptors modulate the effect of the selective serotonin reuptake inhibitor, citalopram on extracellular serotonin levels in the rat prefrontal cortex. Neurosci Res 70(3):334\u2013337. https:\/\/doi.org\/10.1016\/j.neures.2011.03.004","journal-title":"Neurosci Res"},{"key":"3303_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0079-6123(08)00918-7","volume":"172","author":"PJ Fletcher","year":"2008","unstructured":"Fletcher PJ, Le AD, Higgins GA (2008) Serotonin receptors as potential targets for modulation of nicotine use and dependence. Prog Brain Res 172:361\u2013383. https:\/\/doi.org\/10.1016\/S0079-6123(08)00918-7","journal-title":"Prog Brain Res"},{"issue":"5","key":"3303_CR9","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/0006-3223(94)90630-0","volume":"36","author":"D LeMarquand","year":"1994","unstructured":"LeMarquand D, Pihl RO, Benkelfat C (1994) Serotonin and alcohol intake, abuse, and dependence: clinical evidence. Biol Psychiat 36(5):326\u2013337. https:\/\/doi.org\/10.1016\/0006-3223(94)90630-0","journal-title":"Biol Psychiat"},{"issue":"2","key":"3303_CR10","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1124\/jpet.102.037861.2002Nov1;303(2):549-56","volume":"303","author":"R Tao","year":"2002","unstructured":"Tao R, Auerbach SB (2002) Opioid receptor subtypes differentially modulate serotonin efflux in the rat central nervous system. J Pharmacol Exp Ther 303(2):549\u2013556. https:\/\/doi.org\/10.1124\/jpet.102.037861.2002Nov1;303(2):549-56","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20132","key":"3303_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/s0166-4328(01)00253-4","volume":"126","author":"RJ Carey","year":"2001","unstructured":"Carey RJ, DePalma G, Damianopoulos E (2001) Cocaine and serotonin: a role for the 5-HT(1A) receptor site in the mediation of cocaine stimulant effects. Behav Brain Res 126(1\u20132):127\u2013133. https:\/\/doi.org\/10.1016\/s0166-4328(01)00253-4","journal-title":"Behav Brain Res"},{"key":"3303_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1196\/annals.1369.064","volume":"1074","author":"RB Rothman","year":"2006","unstructured":"Rothman RB, Baumann MH (2006) Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs. Ann N Y Acad Sci 1074:245\u2013260. https:\/\/doi.org\/10.1196\/annals.1369.064","journal-title":"Ann N Y Acad Sci"},{"key":"3303_CR13","doi-asserted-by":"crossref","unstructured":"Torrens M, Fonseca F, Mateu G, Farr\u00e9 M (2005) Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis.\u00a0Drug Alcohol Depend 78(1):1\u201322. https:\/\/doi.org\/10.1016\/j.drugalcdep.2004.09.004","DOI":"10.1016\/j.drugalcdep.2004.09.004"},{"issue":"8","key":"3303_CR14","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.4088\/JCP.10m06217","volume":"72","author":"N Iovieno","year":"2011","unstructured":"Iovieno N, Tedeschini E, Bentley KH, Evins AE, Papakostas GI (2011) Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry 72(8):1144\u20131151. https:\/\/doi.org\/10.4088\/JCP.10m06217","journal-title":"J Clin Psychiatry"},{"key":"3303_CR15","doi-asserted-by":"crossref","unstructured":"Stokes PRA, Jokinen T, Amawi S, Qureshi M, Husain MI, Yatham LN, Strang J, Young AH (2020) Pharmacological treatment of mood disorders and comorbid addictions: a systematic review and meta-analysis: Traitement Pharmacologique des Troubles de L'humeur et des D\u00e9pendances Comorbides: Une Revue Syst\u00e9matique et une M\u00e9ta-Analyse.\u00a0Can J Psych. Revue canadienne de psychiatrie\u00a065(11):749\u2013769. https:\/\/doi.org\/10.1177\/0706743720915420","DOI":"10.1177\/0706743720915420"},{"issue":"15","key":"3303_CR16","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.291.15.1887","volume":"291","author":"EV Nunes","year":"2004","unstructured":"Nunes EV, Levin FR (2004) Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA 291(15):1887\u20131896. https:\/\/doi.org\/10.1001\/jama.291.15.1887","journal-title":"JAMA"},{"issue":"1","key":"3303_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/add.15625","volume":"117","author":"S Virtanen","year":"2022","unstructured":"Virtanen S, Lagerberg T, Khemiri L, Suvisaari J, Larsson H, Lichtenstein P, Chang Z, Latvala A (2022) Association of selective serotonin reuptake inhibitor (SSRI) treatment with acute substance misuse outcomes. Addiction (Abingdon, England) 117(1):234\u2013242. https:\/\/doi.org\/10.1111\/add.15625","journal-title":"Addiction (Abingdon, England)"},{"key":"3303_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann T, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical research ed) 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ (Clinical research ed)"},{"key":"3303_CR19","doi-asserted-by":"crossref","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clini Res ed) 366","DOI":"10.1136\/bmj.l4898"},{"key":"3303_CR20","unstructured":"Borenstein M, Cohen J (1988).\u00a0Statistical power analysis: a computer program. Lawrence Erlbaum Associaties, Incorporated"},{"key":"3303_CR21","doi-asserted-by":"publisher","DOI":"10.1201\/9781003107347","volume-title":"In: Doing Meta-Analysis with R","author":"M Harrer","year":"2021","unstructured":"Harrer M, Cuijpers P, Furukawa TA, Ebert DD (2021) In: Doing Meta-Analysis with R. Chapman & Hall\/CRC, Boca Raton, FL"},{"key":"3303_CR22","doi-asserted-by":"crossref","unstructured":"Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR (1999) Methods in health service research. An introduction to Bayesian methods in health technology assessment.\u00a0BMJ Clin Res Ed\u00a0319(7208):508\u2013512. https:\/\/doi.org\/10.1136\/bmj.319.7208.508","DOI":"10.1136\/bmj.319.7208.508"},{"issue":"3","key":"3303_CR23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3758\/s13423-020-01798-5","volume":"28","author":"J van Doorn","year":"2021","unstructured":"van Doorn J, van den Bergh D, B\u00f6hm U, Dablander F, Derks K, Draws T, Etz A, Evans NJ, Gronau QF et al (2021) The JASP guidelines for conducting and reporting a Bayesian analysis. Psychon Bull Rev 28(3):813\u2013826. https:\/\/doi.org\/10.3758\/s13423-020-01798-5","journal-title":"Psychon Bull Rev"},{"issue":"2","key":"3303_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.drugalcdep.2003.11.015","volume":"74","author":"KM Carpenter","year":"2004","unstructured":"Carpenter KM, Brooks AC, Vosburg SK, Nunes EV (2004) The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients: a controlled clinical trial. Drug Alcohol Depend 74(2):123\u2013134. https:\/\/doi.org\/10.1016\/j.drugalcdep.2003.11.015","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"3303_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/s0165-0327(01)00419-0","volume":"72","author":"AJ Dean","year":"2002","unstructured":"Dean AJ, Bell J, Mascord DJ, Parker G, Christie MJ (2002) A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms. J Affect Disord 72(1):85\u201390. https:\/\/doi.org\/10.1016\/s0165-0327(01)00419-0","journal-title":"J Affect Disord"},{"issue":"3","key":"3303_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/s0376-8716(98)00032-5","volume":"50","author":"I Petrakis","year":"1998","unstructured":"Petrakis I, Carroll KM, Nich C, Gordon L, Kosten T, Rounsaville B (1998) Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug Alcohol Depend 50(3):221\u2013226. https:\/\/doi.org\/10.1016\/s0376-8716(98)00032-5","journal-title":"Drug Alcohol Depend"},{"key":"3303_CR27","doi-asserted-by":"crossref","unstructured":"Poling J, Pruzinsky R, Kosten TR, Gonsai K., Sofuoglu M, Gonzalez G et al (2007) Clinical efficacy of citalopram alone or augmented with bupropion in methadone-stabilized patients.\u00a0Am J Addict 16(3):187\u2013194. https:\/\/doi.org\/10.1080\/10550490701375640","DOI":"10.1080\/10550490701375640"},{"issue":"7","key":"3303_CR28","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/s0006-3223(97)00509-x","volume":"44","author":"A Roy","year":"1998","unstructured":"Roy A (1998) Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biol Psychiat 44(7):633\u2013637. https:\/\/doi.org\/10.1016\/s0006-3223(97)00509-x","journal-title":"Biol Psychiat"},{"issue":"2","key":"3303_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/00004714-200104000-00005","volume":"21","author":"HM Pettinati","year":"2001","unstructured":"Pettinati HM, Volpicelli JR, Luck G, Kranzler HR, Rukstalis MR, Cnaan A (2001) Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol 21(2):143\u2013153. https:\/\/doi.org\/10.1097\/00004714-200104000-00005","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"3303_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1055\/s-2007-979538","volume":"29","author":"J Tiihonen","year":"1996","unstructured":"Tiihonen J, Ryyn\u00e4nen OP, Kauhanen J, Hakola HP, Salaspuro M (1996) Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study. Pharmacopsychiatry 29(1):27\u201329. https:\/\/doi.org\/10.1055\/s-2007-979538","journal-title":"Pharmacopsychiatry"},{"key":"3303_CR31","doi-asserted-by":"crossref","unstructured":"Gorelick DA, Paredes A(1992) Effect of fluoxetine on alcohol consumption in male alcoholics.\u00a0Alcohol Clinic Exp Res 16(2):261\u2013265. https:\/\/doi.org\/10.1111\/j.1530-0277.1992.tb01373.x","DOI":"10.1111\/j.1530-0277.1992.tb01373.x"},{"issue":"2","key":"3303_CR32","first-page":"297","volume":"31","author":"JR Cornelius","year":"1995","unstructured":"Cornelius JR, Salloum IM, Cornelius MD, Perel JM, Ehler JG, Jarrett PJ et al (1995) Preliminary report: double-blind, placebo-controlled study of fluoxetine in depressed alcoholics. Psychopharmacol Bull 31(2):297\u2013303","journal-title":"Psychopharmacol Bull"},{"key":"3303_CR33","unstructured":"Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ (1997) Double-blind fluoxetine in depressed alcoholic smokers.\u00a0Psychopharmacol Bull 33(1):165\u2013170"},{"issue":"3","key":"3303_CR34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/ajp.152.3.391","volume":"152","author":"HR Kranzler","year":"1995","unstructured":"Kranzler HR, Burleson JA, Korner P, Del Boca FK, Bohn MJ, Brown J et al (1995) Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 152(3):391\u2013397. https:\/\/doi.org\/10.1176\/ajp.152.3.391","journal-title":"Am J Psychiatry"},{"issue":"2","key":"3303_CR35","first-page":"109","volume":"11","author":"L Janiri","year":"1996","unstructured":"Janiri L, Gobbi G, Mannelli P, Pozzi G, Serretti A, Tempesta E (1996) Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. Int Clin Psychopharmacol 11(2):109\u2013117","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"3303_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/01.jcp.0000194620.61868.35","volume":"26","author":"HR Kranzler","year":"2006","unstructured":"Kranzler HR, Mueller T, Cornelius J, Pettinati HM, Moak D, Martin PR et al (2006) Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol 26(1):13\u201320. https:\/\/doi.org\/10.1097\/01.jcp.0000194620.61868.35","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"3303_CR37","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/alcalc\/agg124","volume":"38","author":"A Gual","year":"2003","unstructured":"Gual A, Balcells M, Torres M, Madrigal M, Diez T, Serrano L (2003) Sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder: a randomized controlled trial. Alcohol and alcoholism (Oxford, Oxfordshire) 38(6):619\u2013625. https:\/\/doi.org\/10.1093\/alcalc\/agg124","journal-title":"Alcohol and alcoholism (Oxford, Oxfordshire)"},{"key":"3303_CR38","doi-asserted-by":"crossref","unstructured":"Charney DA, Heath LM, Zikos E, Palacios\u2010Boix J, Gill KJ (2015) Poorer drinking outcomes with citalopram treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial.\u00a0Alcohol Clini Exp Re 39(9):1756\u20131765. https:\/\/doi.org\/10.1111\/acer.12802","DOI":"10.1111\/acer.12802"},{"issue":"10","key":"3303_CR39","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.addbeh.2009.03.008","volume":"34","author":"JR Cornelius","year":"2009","unstructured":"Cornelius JR, Bukstein OG, Wood DS, Kirisci L, Douaihy A, Clark DB (2009) Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder. Addict Behav 34(10):905\u2013909. https:\/\/doi.org\/10.1016\/j.addbeh.2009.03.008","journal-title":"Addict Behav"},{"issue":"6","key":"3303_CR40","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/1099-1077(200008)15:6<461:AID-HUP209>3.0.C.O.;2-J","volume":"15","author":"D Deas","year":"2000","unstructured":"Deas D, Randall CL, Roberts JS, Anton RF (2000) A double-blind, placebo-controlled trial of sertraline in depressed adolescent alcoholics: a pilot study. Hum Psychopharmacol 15(6):461\u2013469. https:\/\/doi.org\/10.1002\/1099-1077(200008)15:6%3c461:AID-HUP209%3e3.0.C.O.;2-J","journal-title":"Hum Psychopharmacol"},{"key":"3303_CR41","doi-asserted-by":"publisher","unstructured":"Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM, Thase ME, Black A (1997) Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial.\u00a0Arch General Psych\u00a054(8):700\u2013705.\u00a0https:\/\/doi.org\/10.1001\/archpsyc.1997.01830200024004","DOI":"10.1001\/archpsyc.1997.01830200024004"},{"issue":"6","key":"3303_CR42","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/01.jcp.0000095346.32154.41","volume":"23","author":"DH Moak","year":"2003","unstructured":"Moak DH, Anton RF, Latham PK, Voronin KE, Waid RL, Durazo-Arvizu R (2003) Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial. J Clin Psychopharmacol 23(6):553\u2013562. https:\/\/doi.org\/10.1097\/01.jcp.0000095346.32154.41","journal-title":"J Clin Psychopharmacol"},{"key":"3303_CR43","doi-asserted-by":"publisher","unstructured":"Cornelius JR, Salloum IM, Haskett RF, Daley DC, Cornelius MD, Thase ME et al (2000) Fluoxetine versus placebo in depressed alcoholics: a 1-year follow-up study.\u00a0Addict Behave 25(2):307\u2013310. https:\/\/doi.org\/10.1016\/s0306-4603(99)00065-9","DOI":"10.1016\/s0306-4603(99)00065-9"},{"issue":"4","key":"3303_CR44","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/j.1530-0277.1996.tb01686.x","volume":"20","author":"DI Kabel","year":"1996","unstructured":"Kabel DI, Petty F (1996) A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcohol Clin Exp Res 20(4):780\u2013784. https:\/\/doi.org\/10.1111\/j.1530-0277.1996.tb01686.x","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"3303_CR45","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/clpt.1990.62","volume":"47","author":"CA Naranjo","year":"1990","unstructured":"Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Remus D, Sellers EM (1990) Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther 47(4):490\u2013498. https:\/\/doi.org\/10.1038\/clpt.1990.62","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3303_CR46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00004850-199409000-00004","volume":"9","author":"CA Naranjo","year":"1994","unstructured":"Naranjo CA, Poulos CX, Bremner KE, Lanctot KL (1994) Fluoxetine attenuates alcohol intake and desire to drink. Int Clin Psychopharmacol 9(3):163\u2013172. https:\/\/doi.org\/10.1097\/00004850-199409000-00004","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"3303_CR47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.drugalcdep.2003.11.012","volume":"74","author":"J Chick","year":"2004","unstructured":"Chick J, Aschauer H, Hornik K (2004) Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology. Drug Alcohol Depend 74(1):61\u201370. https:\/\/doi.org\/10.1016\/j.drugalcdep.2003.11.012","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"3303_CR48","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1046\/j.1360-0443.1995.9018712.x","volume":"90","author":"CA Naranjo","year":"1995","unstructured":"Naranjo CA, Bremner KE, Lanctot KL (1995) Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction (Abingdon, England) 90(1):87\u201399. https:\/\/doi.org\/10.1046\/j.1360-0443.1995.9018712.x","journal-title":"Addiction (Abingdon, England)"},{"issue":"11","key":"3303_CR49","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0011-393X(02)80096-0","volume":"63","author":"H Co\u015fkunol","year":"2002","unstructured":"Co\u015fkunol H, G\u00f6kden O, Ercan ES, Bayraktar E, Tu\u011flular I, Sayg\u0131l\u0131 R (2002) Long-term efficacy of sertraline in the prevention of alcoholic relapses in alcohol-dependent patients: a single-center, double-blind, randomized, placebo-controlled, parallel-group study. Curr Ther Res 63(11):759\u2013771. https:\/\/doi.org\/10.1016\/S0011-393X(02)80096-0","journal-title":"Curr Ther Res"},{"issue":"2","key":"3303_CR50","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/oxfordjournals.alcalc.a008371","volume":"33","author":"SM Angelone","year":"1998","unstructured":"Angelone SM, Bellini L, Di Bella D, Catalano M (1998) Effects of fluvoxamine and citalopram in maintaining abstinence in a sample of Italian detoxified alcoholics. Alcohol and alcoholism (Oxford, Oxfordshire) 33(2):151\u2013156. https:\/\/doi.org\/10.1093\/oxfordjournals.alcalc.a008371","journal-title":"Alcohol and alcoholism (Oxford, Oxfordshire)"},{"issue":"6","key":"3303_CR51","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/clpt.1992.85","volume":"51","author":"CA Naranjo","year":"1992","unstructured":"Naranjo CA, Poulos CX, Bremner KE, Lanct\u00f4t KL (1992) Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers. Clin Pharmacol Ther 51(6):729\u2013739. https:\/\/doi.org\/10.1038\/clpt.1992.85","journal-title":"Clin Pharmacol Ther"},{"key":"3303_CR52","doi-asserted-by":"crossref","unstructured":"Eriksson M, Berggren U, Blennow K, Fahlke C, Balldin J (2001) Further investigation of citalopram on alcohol consumption in heavy drinkers: responsiveness possibly linked to the DRD2 A2\/A2 genotype.\u00a0Alcohol (Fayetteville, N.Y.)\u00a024(1):15\u201323. https:\/\/doi.org\/10.1016\/s0741-8329(01)00137-9","DOI":"10.1016\/S0741-8329(01)00137-9"},{"issue":"5","key":"3303_CR53","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/j.1530-0277.1994.tb00093.x","volume":"18","author":"J Balldin","year":"1994","unstructured":"Balldin J, Berggren U, Engel J, Eriksson M, H\u00e5rd E, S\u00f6derpalm B (1994) Effect of citalopram on alcohol intake in heavy drinkers. Alcohol Clin Exp Res 18(5):1133\u20131136. https:\/\/doi.org\/10.1111\/j.1530-0277.1994.tb00093.x","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"3303_CR54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1753-2000-3-11","volume":"3","author":"RL Findling","year":"2009","unstructured":"Findling RL, Pagano ME, McNamara NK, Stansbrey RJ, Faber JE, Lingler J et al (2009) The short-term safety and efficacy of fluoxetine in depressed adolescents with alcohol and cannabis use disorders: a pilot randomized placebo-controlled trial. Child Adolesc Psychiatry Ment Health 3(1):11. https:\/\/doi.org\/10.1186\/1753-2000-3-11","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"3303_CR55","unstructured":"Habrat B, Za\u0142oga B (2006) Skuteczno\u015b\u0107 i tolerancja tianeptyny w leczeniu zaburze\u0144 depresyjnych u pacjent\u00f3w uzaleznionych od alkoholu. wieloo\u015brodkowe badanie kontrolowane metoda podw\u00f3jnie slepej pr\u00f3by z uzyciem fluwoksaminy [A double-blind controlled study of the efficacy and acceptability of tianeptine in comparison with fluvoxamine in the treatment of depressed alcoholic patients].\u00a0Psychiatria Polska\u00a040(3):579\u2013597"},{"issue":"3","key":"3303_CR56","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/00952990701313686","volume":"33","author":"FG Moeller","year":"2007","unstructured":"Moeller FG, Schmitz JM, Steinberg JL, Green CM, Reist C, Lai LY et al (2007) Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Am J Drug Alcohol Abuse 33(3):367\u2013378. https:\/\/doi.org\/10.1080\/00952990701313686","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"1","key":"3303_CR57","first-page":"117","volume":"34","author":"JR Cornelius","year":"1998","unstructured":"Cornelius JR, Salloum IM, Thase ME, Haskett RF (1998) Fluoxetine versus placebo in depressed alcoholic cocaine abusers. Psychopharmacol Bull 34(1):117\u2013121","journal-title":"Psychopharmacol Bull"},{"issue":"3","key":"3303_CR58","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s0376-8716(00)00208-8","volume":"63","author":"JM Schmitz","year":"2001","unstructured":"Schmitz JM, Averill P, Stotts AL, Moeller FG, Rhoades HM, Grabowski J (2001) Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug Alcohol Depend 63(3):207\u2013214. https:\/\/doi.org\/10.1016\/s0376-8716(00)00208-8","journal-title":"Drug Alcohol Depend"},{"key":"3303_CR59","doi-asserted-by":"publisher","unstructured":"Oliveto A, Poling J, Mancino MJ, Williams DK, Thostenson J, Pruzinsky R et al (2012) Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms. Addiction (Abingdon, England) 107(1):131\u2013141. https:\/\/doi.org\/10.1111\/j.1360-0443.2011.03552.x","DOI":"10.1111\/j.1360-0443.2011.03552.x"},{"issue":"3","key":"3303_CR60","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jsat.2010.11.010","volume":"40","author":"EL Winstanley","year":"2011","unstructured":"Winstanley EL, Bigelow GE, Silverman K, Johnson RE, Strain EC (2011) A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients. J Subst Abuse Treat 40(3):255\u2013264. https:\/\/doi.org\/10.1016\/j.jsat.2010.11.010","journal-title":"J Subst Abuse Treat"},{"key":"3303_CR61","doi-asserted-by":"crossref","unstructured":"Covi L, Hess JM, Kreiter NA, Haertzen CA (1995) Effects of combined fluoxetine and counseling in the outpatient treatment of cocaine abusers.\u00a0Am J Drug Alcohol Abuse\u00a021(3):327\u2013344. https:\/\/doi.org\/10.3109\/00952999509002701","DOI":"10.3109\/00952999509002701"},{"issue":"2","key":"3303_CR62","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0376-8716(96)01233-1","volume":"41","author":"SL Batki","year":"1996","unstructured":"Batki SL, Washburn AM, Delucchi K, Jones RT (1996) A controlled trial of fluoxetine in crack cocaine dependence. Drug Alcohol Depend 41(2):137\u2013142. https:\/\/doi.org\/10.1016\/0376-8716(96)01233-1","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"3303_CR63","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/JCP.0000000000000062","volume":"34","author":"MJ Mancino","year":"2014","unstructured":"Mancino MJ, McGaugh J, Chopra MP, Guise JB, Cargile C, Williams DK et al (2014) Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms. J Clin Psychopharmacol 34(2):234\u2013239. https:\/\/doi.org\/10.1097\/JCP.0000000000000062","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"3303_CR64","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/s0306-4603(98)00050-1","volume":"24","author":"JR Cornelius","year":"1999","unstructured":"Cornelius JR, Salloum IM, Haskett RF, Ehler JG, Jarrett PJ, Thase ME et al (1999) Fluoxetine versus placebo for the marijuana use of depressed alcoholics. Addict Behav 24(1):111\u2013114. https:\/\/doi.org\/10.1016\/s0306-4603(98)00050-1","journal-title":"Addict Behav"},{"issue":"1\u20132","key":"3303_CR65","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.drugalcdep.2010.05.010","volume":"112","author":"JR Cornelius","year":"2010","unstructured":"Cornelius JR, Bukstein OG, Douaihy AB, Clark DB, Chung TA, Daley DC et al (2010) Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug Alcohol Depend 112(1\u20132):39\u201345. https:\/\/doi.org\/10.1016\/j.drugalcdep.2010.05.010","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"3303_CR66","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/00952990.2013.819362","volume":"40","author":"AM Weinstein","year":"2014","unstructured":"Weinstein AM, Miller H, Bluvstein I, Rapoport E, Schreiber S, Bar-Hamburger R et al (2014) Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study. Am J Drug Alcohol Abuse 40(1):16\u201322. https:\/\/doi.org\/10.3109\/00952990.2013.819362","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"10","key":"3303_CR67","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1176\/appi.ajp.159.10.1731","volume":"159","author":"LS Covey","year":"2002","unstructured":"Covey LS, Glassman AH, Stetner F, Rivelli S, Stage K (2002) A randomized trial of sertraline as a cessation aid for smokers with a history of major depression. Am J Psychiatry 159(10):1731\u20131737. https:\/\/doi.org\/10.1176\/appi.ajp.159.10.1731","journal-title":"Am J Psychiatry"},{"issue":"4","key":"3303_CR68","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1037\/\/0022-006x.70.4.887","volume":"70","author":"R Niaura","year":"2002","unstructured":"Niaura R, Spring B, Borrelli B, Hedeker D, Goldstein MG, Keuthen N et al (2002) Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. J Consult Clin Psychol 70(4):887\u2013896. https:\/\/doi.org\/10.1037\/\/0022-006x.70.4.887","journal-title":"J Consult Clin Psychol"},{"issue":"5","key":"3303_CR69","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1080\/10550490490512762","volume":"13","author":"KK Saules","year":"2004","unstructured":"Saules KK, Schuh LM, Arfken CL, Reed K, Kilbey MM, Schuster CR (2004) Double-blind placebo-controlled trial of fluoxetine in smoking cessation treatment including nicotine patch and cognitive-behavioral group therapy. Am J Addict 13(5):438\u2013446. https:\/\/doi.org\/10.1080\/10550490490512762","journal-title":"Am J Addict"},{"issue":"5","key":"3303_CR70","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1037\/0022-006X.68.5.883","volume":"68","author":"JD Killen","year":"2000","unstructured":"Killen JD, Fortmann SP, Schatzberg AF, Hayward C, Sussman L, Rothman M et al (2000) Nicotine patch and paroxetine for smoking cessation. J Consult Clin Psychol 68(5):883\u2013889","journal-title":"J Consult Clin Psychol"},{"issue":"11","key":"3303_CR71","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1001\/archpedi.161.11.1026","volume":"161","author":"PD Riggs","year":"2007","unstructured":"Riggs PD, Mikulich-Gilbertson SK, Davies RD, Lohman M, Klein C, Stover SK (2007) A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. Arch Pediatr Adolesc Med 161(11):1026\u20131034. https:\/\/doi.org\/10.1001\/archpedi.161.11.1026","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"7","key":"3303_CR72","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1046\/j.1360-0443.1999.94710076.x","volume":"94","author":"T Blondal","year":"1999","unstructured":"Blondal T, Gudmundsson LJ, Tomasson K, Jonsdottir D, Hilmarsdottir H, Kristjansson F et al (1999) The effects of fluoxetine combined with nicotine inhalers in smoking cessation\u2013a randomized trial. Addiction (Abingdon, England) 94(7):1007\u20131015. https:\/\/doi.org\/10.1046\/j.1360-0443.1999.94710076.x","journal-title":"Addiction (Abingdon, England)"},{"issue":"1","key":"3303_CR73","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.drugalcdep.2006.03.005","volume":"85","author":"S Shoptaw","year":"2006","unstructured":"Shoptaw S, Huber A, Peck J, Yang X, Liu J, Dang J et al (2006) Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend 85(1):12\u201318. https:\/\/doi.org\/10.1016\/j.drugalcdep.2006.03.005","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"3303_CR74","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/01.alc.0000156129.98265.57","volume":"29","author":"KT Brady","year":"2005","unstructured":"Brady KT, Sonne S, Anton RF, Randall CL, Back SE, Simpson K (2005) Sertraline in the treatment of co-occurring alcohol dependence and post-traumatic stress disorder. Alcohol Clin Exp Res 29(3):395\u2013401. https:\/\/doi.org\/10.1097\/01.alc.0000156129.98265.57","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"3303_CR75","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1037\/a0038719","volume":"83","author":"DA Hien","year":"2015","unstructured":"Hien DA, Levin FR, Ruglass LM, L\u00f3pez-Castro T, Papini S, Hu MC et al (2015) Combining seeking safety with sertraline for PTSD and alcohol use disorders: a randomized controlled trial. J Consult Clin Psychol 83(2):359\u2013369. https:\/\/doi.org\/10.1037\/a0038719","journal-title":"J Consult Clin Psychol"},{"issue":"4","key":"3303_CR76","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/da.1077","volume":"14","author":"CL Randall","year":"2001","unstructured":"Randall CL, Johnson MR, Thevos AK, Sonne SC, Thomas SE, Willard SL et al (2001) Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress Anxiety 14(4):255\u2013262. https:\/\/doi.org\/10.1002\/da.1077","journal-title":"Depress Anxiety"},{"issue":"4","key":"3303_CR77","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/da.1077","volume":"14","author":"SW Book","year":"2001","unstructured":"Book SW, Thomas SE, Randall PK, Randall CL (2001) Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress Anxiety 14(4):255\u2013262. https:\/\/doi.org\/10.1002\/da.1077","journal-title":"Depress Anxiety"},{"key":"3303_CR78","doi-asserted-by":"crossref","unstructured":"Book SW, Thomas SE, Smith JP, Randall PK, Kushner MG, Bernstein GA, Specker SM, Miller PM, Randall CL (2013) Treating individuals with social anxiety disorder and at-risk drinking: phasing in a brief alcohol intervention following paroxetine.\u00a0J Anxiety Disord\u00a027(2):252\u2013258. https:\/\/doi.org\/10.1016\/j.janxdis.2013.02.008","DOI":"10.1016\/j.janxdis.2013.02.008"},{"issue":"1","key":"3303_CR79","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1530-0277.2007.00546.x","volume":"32","author":"SE Thomas","year":"2008","unstructured":"Thomas SE, Randall PK, Book SW, Randall CL (2008) A complex relationship between co-occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking? Alcohol Clin Exp Res 32(1):77\u201384. https:\/\/doi.org\/10.1111\/j.1530-0277.2007.00546.x","journal-title":"Alcohol Clin Exp Res"},{"issue":"7","key":"3303_CR80","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/j.1530-0277.2008.00682.x","volume":"32","author":"SS O'Malley","year":"2008","unstructured":"O\u2019Malley SS, Robin RW, Levenson AL, GreyWolf I, Chance LE, Hodgkinson CA et al (2008) Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. Alcohol Clin Exp Res 32(7):1271\u20131283. https:\/\/doi.org\/10.1111\/j.1530-0277.2008.00682.x","journal-title":"Alcohol Clin Exp Res"},{"issue":"1\u20133","key":"3303_CR81","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.drugalcdep.2008.06.006","volume":"99","author":"CK Farren","year":"2009","unstructured":"Farren CK, Scimeca M, Wu R, Malley SO (2009) A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence. Drug Alcohol Depend 99(1\u20133):317\u2013321. https:\/\/doi.org\/10.1016\/j.drugalcdep.2008.06.006","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"3303_CR82","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/npp.2011.283","volume":"37","author":"IL Petrakis","year":"2012","unstructured":"Petrakis IL, Ralevski E, Desai N, Trevisan L, Gueorguieva R, Rounsaville B et al (2012) Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. Neuropsychopharmacology\u202f: official publication of the American College of Neuropsychopharmacology 37(4):996\u20131004. https:\/\/doi.org\/10.1038\/npp.2011.283","journal-title":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology"},{"issue":"6","key":"3303_CR83","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1176\/appi.ajp.2009.08060852","volume":"167","author":"HM Pettinati","year":"2010","unstructured":"Pettinati HM, Oslin DW, Kampman KM, Dundon WD, Xie H, Gallis T et al (2010) A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry 167(6):668\u2013675. https:\/\/doi.org\/10.1176\/appi.ajp.2009.08060852","journal-title":"Am J Psychiatry"},{"issue":"2","key":"3303_CR84","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/JCP.0000000000000287","volume":"35","author":"SJ Adamson","year":"2015","unstructured":"Adamson SJ, Sellman JD, Foulds JA, Frampton CM, Deering D, Dunn A et al (2015) A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression. J Clin Psychopharmacol 35(2):143\u2013149. https:\/\/doi.org\/10.1097\/JCP.0000000000000287","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"3303_CR85","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/JCP.0b013e3182726764","volume":"32","author":"J Witte","year":"2012","unstructured":"Witte J, Bentley K, Evins AE, Clain AJ, Baer L, Pedrelli P et al (2012) A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder. J Clin Psychopharmacol 32(6):787\u2013796. https:\/\/doi.org\/10.1097\/JCP.0b013e3182726764","journal-title":"J Clin Psychopharmacol"},{"key":"3303_CR86","doi-asserted-by":"crossref","unstructured":"Muhonen LH, Lahti J, Sinclair D, L\u00f6nnqvist J, Alho H (2008) Treatment of alcohol dependence in patients with comorbid major depressive disorder--predictors for the outcomes with memantine and escitalopram medication.\u00a0Substance Abuse Treatment, Prevention Policy\u00a03:20. https:\/\/doi.org\/10.1186\/1747-597X-3-20","DOI":"10.1186\/1747-597X-3-20"},{"issue":"3","key":"3303_CR87","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1177\/0269881112472563","volume":"27","author":"DH Han","year":"2013","unstructured":"Han DH, Kim SM, Choi JE, Min KJ, Renshaw PF (2013) Adjunctive aripiprazole therapy with escitalopram in patients with comorbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence. Journal of psychopharmacology (Oxford, England) 27(3):282\u2013291. https:\/\/doi.org\/10.1177\/0269881112472563","journal-title":"Journal of psychopharmacology (Oxford, England)"},{"issue":"3","key":"3303_CR88","doi-asserted-by":"publisher","first-page":"392","DOI":"10.4088\/jcp.v69n0308","volume":"69","author":"LH Muhonen","year":"2008","unstructured":"Muhonen LH, L\u00f6nnqvist J, Juva K, Alho H (2008) Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry 69(3):392\u2013399. https:\/\/doi.org\/10.4088\/jcp.v69n0308","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"3303_CR89","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1046\/j.1360-0443.1998.9357399.x","volume":"93","author":"MA Landabaso","year":"1998","unstructured":"Landabaso MA, Iraurgi I, Jimenez-Lerma JM, Sanz J, Corres BF, Araluce K et al (1998) A randomized trial of adding fluoxetine to a naltrexone treatment programme for heroin addicts. Addiction (Abingdon, England) 93(5):739\u2013744. https:\/\/doi.org\/10.1046\/j.1360-0443.1998.9357399.x","journal-title":"Addiction (Abingdon, England)"},{"issue":"3","key":"3303_CR90","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1080\/10550490290088009","volume":"11","author":"CK Farren","year":"2002","unstructured":"Farren CK, O\u2019Malley S (2002) A pilot double blind placebo-controlled trial of sertraline with naltrexone in the treatment of opiate dependence. Am J Addict 11(3):228\u2013234. https:\/\/doi.org\/10.1080\/10550490290088009","journal-title":"Am J Addict"},{"key":"3303_CR91","doi-asserted-by":"crossref","unstructured":"Zorick T, Sugar CA, Hellemann G, Shoptaw S, London ED (2011) Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine.\u00a0Drug Alcohol Depend 118(2\u20133):500\u2013503.\u00a0https:\/\/doi.org\/10.1016\/j.drugalcdep.2011.04.015","DOI":"10.1016\/j.drugalcdep.2011.04.015"},{"issue":"8","key":"3303_CR92","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/ajad.12635","volume":"26","author":"M Bashiri","year":"2017","unstructured":"Bashiri M, Mancino MJ, Stanick VA, Thostenson J, Kosten TR, Oliveto AH (2017) Moderators of response to sertraline versus placebo among recently abstinent, cocaine dependent patients: a retrospective analysis of two clinical trials. Am J Addict 26(8):807\u2013814. https:\/\/doi.org\/10.1111\/ajad.12635","journal-title":"Am J Addict"},{"key":"3303_CR93","doi-asserted-by":"crossref","unstructured":"Kranzler HR, Armeli S, Tennen H (2012) Post-treatment outcomes in a double-blind, randomized trial of sertraline for alcohol dependence.\u00a0Alcohol Clinic Exp Res 36(4):739\u2013744. https:\/\/doi.org\/10.1111\/j.1530-0277.2011.01659.x4","DOI":"10.1111\/j.1530-0277.2011.01659.x"},{"key":"3303_CR94","doi-asserted-by":"publisher","first-page":"31858","DOI":"10.3402\/ejpt.v7.31858","volume":"7","author":"B Kelmendi","year":"2016","unstructured":"Kelmendi B, Adams TG, Yarnell S, Southwick S, Abdallah C, Krystal JH (2016) PTSD: from neurobiology to pharmacological treatments. Eur J Psychotraumatol 7:31858. https:\/\/doi.org\/10.3402\/ejpt.v7.31858","journal-title":"Eur J Psychotraumatol"},{"issue":"3","key":"3303_CR95","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/s0306-4522(01)00509-7","volume":"109","author":"H Hermann","year":"2002","unstructured":"Hermann H, Marsicano G, Lutz B (2002) Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109(3):451\u2013460. https:\/\/doi.org\/10.1016\/s0306-4522(01)00509-7","journal-title":"Neuroscience"},{"issue":"4","key":"3303_CR96","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/add.14866","volume":"115","author":"P Brenner","year":"2020","unstructured":"Brenner P, Brandt L, Li G, DiBernardo A, Bod\u00e9n R, Reutfors J (2020) Substance use disorders and risk for treatment resistant depression: a population-based, nested case-control study. Addiction 115(4):768\u2013777","journal-title":"Addiction"},{"issue":"3\u20134","key":"3303_CR97","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/19371918.2013.774675","volume":"28","author":"KT Brady","year":"2013","unstructured":"Brady KT, Haynes LF, Hartwell KJ, Killeen TK (2013) Substance use disorders and anxiety: a treatment challenge for social workers. Social work in public health 28(3\u20134):407\u2013423. https:\/\/doi.org\/10.1080\/19371918.2013.774675","journal-title":"Social work in public health"},{"key":"3303_CR98","doi-asserted-by":"publisher","unstructured":"Berenz EC, Coffey SF (2012) Treatment of co-occurring post-traumatic stress disorder and substance use disorders.\u00a0Curr Psych Rep 14(5):469\u2013477. https:\/\/doi.org\/10.1007\/s11920-012-0300-0","DOI":"10.1007\/s11920-012-0300-0"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03303-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03303-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03303-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T08:06:13Z","timestamp":1652515573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03303-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,5]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["3303"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03303-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,5]]},"assertion":[{"value":"11 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The\u00a0authors reviewed anonymized\u00a0data from published literature.\u00a0Therefore, no informed consent or ethical approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}